H.C. Wainwright initiated coverage of Q32 Bio with a Buy rating and $13 price target. The firm says the company's bempikibart targets an opportunity in alopecia areata where current therapies remain limited. Q3 offers a "differentiated approach" to severe alopecia areata with the potential for meaningful and durable disease control, addressing limitations of current therapies related to safety and long-term use, the analyst tells investors in a research note.
